ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy tested on patients with untreatable autoimmune diseases
Disease control Recruiting nowThis is an early-stage safety study testing a single infusion of YTS109 cells in 18 adults with severe autoimmune diseases that have not responded to standard treatments. The main goal is to check for side effects and see how the body handles the cells. Researchers will also look…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Radical cell therapy tested for Tough-to-Treat autoimmune conditions
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy called anti-CD19/BCMA universal CAR-T cells in people with severe autoimmune diseases that have not improved with standard treatments. The main goals are to check if the treatment is safe and to see if it can help contr…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New cell therapy tested for patients Who've tried everything else
Disease control Recruiting nowThis is an early safety study testing a single infusion of a new cell therapy called YTS109. It aims to see if the treatment is safe and shows any signs of helping adults with severe autoimmune diseases that have not responded to standard treatments. The study will enroll about 1…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug trial aims to control rare autoimmune disease
Disease control Recruiting nowThis study is testing an investigational drug called tarperprumig for adults with ANCA-associated vasculitis, a rare autoimmune disease that causes blood vessel inflammation. The main goal is to see if the drug is safe and can help patients achieve and maintain disease remission …
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New cell therapy tested for patients with untreatable autoimmune diseases
Disease control Recruiting nowThis is an early-stage study to check the safety of a new cell therapy called YTS109 for adults with severe autoimmune diseases that have not responded to standard treatments. About 18 participants with conditions like lupus, scleroderma, or vasculitis will receive a single infus…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New cell therapy tested for Hard-to-Treat autoimmune conditions
Disease control Recruiting nowThis is an early-stage study to check the safety of a new cell therapy called YTS109 in adults with severe autoimmune diseases that have not improved with standard treatments. About 18 participants with conditions like lupus, Sjogren's syndrome, or vasculitis will receive a singl…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC